Literature DB >> 31580635

Development of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins.

Nobumichi Ohoka, Genichiro Tsuji, Takuji Shoda, Takuma Fujisato, Masaaki Kurihara, Yosuke Demizu, Mikihiko Naito.   

Abstract

Targeted protein degradation using chimeric small molecules such as proteolysis-targeting chimeras (PROTACs) and specific and nongenetic inhibitors of apoptosis protein [IAP]-dependent protein erasers (SNIPERs) is an emerging modality in drug discovery. Here, we expand the repertoire of E3 ligases capable of ubiquitylating target proteins using this system. By incorporating β-naphthoflavone (β-NF) as a ligand, we developed a novel class of chimeric molecules that recruit the arylhydrocarbon receptor (AhR) E3 ligase complex. β-NF-ATRA, a chimeric degrader directed against cellular retinoic acid binding proteins (CRABPs), induced the AhR-dependent degradation of CRABP-1 and CRABP-2 via the ubiquitin-proteasome pathway. A similar compound ITE-ATRA, in which an alternative AhR ligand was used, also degraded CRABP proteins. Finally, we developed a chimeric compound β-NF-JQ1 that is directed against bromodomain-containing (BRD) proteins using β-NF as an AhR ligand. β-NF-JQ1 induced the interaction of AhR and BRD proteins and displayed effective anticancer activity that correlated with protein knockdown activity. These results demonstrate a novel class of chimeric degrader molecules based on the ability to bring a target protein and an AhR E3 ligase into close proximity.

Entities:  

Year:  2019        PMID: 31580635     DOI: 10.1021/acschembio.9b00704

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  16 in total

1.  PROTAC Degraders with Ligands Recruiting MDM2 E3 Ubiquitin Ligase: An Updated Perspective.

Authors:  Xin Han; Wenyi Wei; Yi Sun
Journal:  Acta Mater Med       Date:  2022-05-31

Review 2.  PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).

Authors:  Ming He; Chaoguo Cao; Zhihao Ni; Yongbo Liu; Peilu Song; Shuang Hao; Yuna He; Xiuyun Sun; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2022-06-09

3.  Synthesis and biological evaluation of FICZ analogues as agonists of aryl hydrocarbon receptor.

Authors:  Hao Wu; Binkai Liu; Ka Yang; Gabrielle N Winston-McPherson; Eric D Leisten; Chad M Vezina; William A Ricke; Richard E Peterson; Weiping Tang
Journal:  Bioorg Med Chem Lett       Date:  2020-01-07       Impact factor: 2.823

4.  Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries.

Authors:  Bo Wang; Jin Liu; Ira Tandon; Suzhen Wu; Peng Teng; Jianhua Liao; Weiping Tang
Journal:  Eur J Med Chem       Date:  2021-04-04       Impact factor: 7.088

Review 5.  Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.

Authors:  Yonghan He; Sajid Khan; Zhiguang Huo; Dongwen Lv; Xuan Zhang; Xingui Liu; Yaxia Yuan; Robert Hromas; Mingjiang Xu; Guangrong Zheng; Daohong Zhou
Journal:  J Hematol Oncol       Date:  2020-07-27       Impact factor: 17.388

Review 6.  Structural derivatization strategies of natural phenols by semi-synthesis and total-synthesis.

Authors:  Ding Lin; Senze Jiang; Ailian Zhang; Tong Wu; Yongchang Qian; Qingsong Shao
Journal:  Nat Prod Bioprospect       Date:  2022-03-07

Review 7.  E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points.

Authors:  Aleša Bricelj; Christian Steinebach; Robert Kuchta; Michael Gütschow; Izidor Sosič
Journal:  Front Chem       Date:  2021-07-05       Impact factor: 5.221

Review 8.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

Review 9.  Huntingtin Ubiquitination Mechanisms and Novel Possible Therapies to Decrease the Toxic Effects of Mutated Huntingtin.

Authors:  Annarita Fiorillo; Veronica Morea; Gianni Colotti; Andrea Ilari
Journal:  J Pers Med       Date:  2021-12-06

Review 10.  E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.

Authors:  Tasuku Ishida; Alessio Ciulli
Journal:  SLAS Discov       Date:  2020-11-03       Impact factor: 3.341

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.